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To update the 2016 formal consensus-based guidance for the management of myasthenia gravis
(MG) based on the latest evidence in the literature.
Methods
In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to
develop treatment guidance for MG, and a panel of 15 international experts was convened. The
RAND/UCLA appropriateness method was used to develop consensus recommendations
pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with
the addition of one member to represent South America. All previous recommendations were
reviewed for currency, and new consensus recommendations were developed on topics that
required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous
e-mail votes were used to reach consensus, with modifications to recommendations between
rounds based on the panel input. A simple majority vote (80% of panel members voting “yes”)
was used to approve minor changes in grammar and syntax to improve clarity.
Results
The previous recommendations for thymectomy were updated. New recommendations were
developed for the use of rituximab, eculizumab, and methotrexate as well as for the following
topics: early immunosuppression in ocular MG and MG associated with immune checkpoint
inhibitor treatment.
Conclusion
This updated formal consensus guidance of international MG experts, based on new evidence,
provides recommendations to clinicians caring for patients with MG worldwide.
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Evidence-based recommendations for the treatment of my-
asthenia gravis (MG) have historically been difficult to de-
velop because of limited evidence from studies with a low risk
of bias such as large, well-designed randomized controlled
trial studies (RCTs). To address the lack of uniform, globally
accepted standards for the care of people with MG, the My-
asthenia Gravis Foundation of America (MGFA) appointed a
Task Force in 2013 to develop treatment recommendations
forMG. A panel of 15 international experts in the treatment of
MG was convened and, in 2016, published an international
consensus guidance for the management of MG.1
Results of several new trials of MG treatment have been
published since that guidance statement was published, and in
2019, the panel reviewed the previous recommendations for
currency and identified new topics that may affect practice. All
members of the previous MGFA Task Force participated in
this update; one new member (G.C.) was added to the in-
ternational panel, which now consists of experts from Canada
(M.N.), Chile (G.C.), Germany (A.M.), Italy (A.E.), Japan
(H.M.), Norway (N.E.G.), the Netherlands (J.V.), Spain
(I.I.), UK (J.P.), and USA (P.N., D.S., G.W., M.B., N.K.,
J.M.M., and D.P.R.). All except P.N. were voting members;
P.N. served as the methodologist.
Methods
Topics informing new recommendations were selected based
on a review of studies of the treatment of MG published since
2013. Panel members disclosed any conflicts of interest
(COI) using the Neurology COI disclosure form; all conflicts
were reviewed by the panel co-chairs (D.S. and G.W.). One or
two panel members prepared narrative reviews of the recent
literature and proposed initial recommendations for each
topic. Conflicted panel members abstained from participating
in the literature review and from developing initial recom-
mendation statements for the conflicted topic(s) but partici-
pated in the group discussions and voting to obtain expert
consensus for all topics.
Topics Identified for the Development
of Recommendations
Based on the availability of new clinical trial data that the panel
co-chairs determined may affect previous recommendations
or lend themselves to new recommendations, the following
interventions were selected: thymectomy, rituximab (RTX)
in MG with antibodies to acetylcholine receptors (AChRs)
and muscle-specific kinase (MuSK), eculizumab, and meth-
otrexate (MTX). Recommendations were also developed to
inform early immunosuppression in ocular MG, the role of
physical training/exercise inMG, and themanagement ofMG
associated with immune checkpoint inhibitor treatment.
Physical training/exercise was excluded after review because
of the low quality of evidence informing recommendations.
The RAND/UCLA appropriateness method for formal con-
sensus was used to obtain consensus, with the same a priori
assumptions regarding treatment availability and costs as in
the initial guidance document.1,2 All voting was conducted by
e-mail and the responses returned only to the methodologist
to avoid the potential for panel members’ opinions and votes
being influenced by others. Topics were voted on sequen-
tially, although rounds of voting for different topics frequently
overlapped for efficiency. All recommendation statements
were edited after the first round of voting by the co-chairs and
methodologist in response to the panel’s suggestions for
changes and depending on whether consensus was reached or
not. The edited recommendations were sent by e-mail to the
panel along with collated panel comments from the previous
round for voting. The process was repeated for up to 3 rounds
of voting, as needed. Recommendations that did not achieve
consensus after 3 rounds of voting were discarded. The panel
rated each recommendation for appropriateness on a 9-point
scale (1–3: inappropriate, 4–6: uncertain, and 7–9: appro-
priate). Median and range were calculated for each recom-
mendation to assess appropriateness and agreement per the
RAM method. Tables e1-e10, doi:10.5061/dryad.6hdr7sqxx,
summarize all the recommendations of the original guideline
that are still current plus those from the present update.
Table 1 provides an update of drugs to avoid or use with
caution in MG.
Results
All recommendations below achieved panel consensus
agreement as being appropriate, and these recommendations
should be considered extensions or additions to recommen-
dations made in the initial international consensus guidance.1
Glossary
AChR = acetylcholine receptor; AChR-Ab+ = AChR-positive; COI = conflicts of interest; CSR = complete stable remission;
CTLA-4 = cytotoxic T-lymphocyte–associated protein 4; ICP = immune checkpoint; irAE = immune-related adverse event;
IS = immunosuppressive; IVIg = intravenous immunoglobulin; MG = myasthenia gravis; MG-ADL = MG-activity of daily
living; MGC = MG-composite; MGFA = Myasthenia Gravis Foundation of America; MM = minimal manifestation; MMT =
Manual Muscle testing; MTX = methotrexate; MuSK = muscle specific kinase; OLE = open-label extension; PD-1 =
programmed cell death protein 1; PDL-1 = programmed cell death ligand 1; PIS = postintervention status;QMG = quantitative
MG; RCT = randomized controlled trial; REGAIN = refractory generalized nonthymomatous AChR-Ab+ MG; RTX =
rituximab.
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The range outside of the “appropriate” category (7–9) indi-
cates the breadth of opinions (dispersion) within the panel.
Thymectomy
The multicenter, randomized, rater-blinded trial of thymec-
tomy in MG (MGTX) enrolled patients younger than 65
years with AChR-positive (AChR-Ab+) generalized non-
thymomatous MG of <5 years duration.3 Sixty-six subjects
underwent extended transsternal thymectomy and received
prednisone using a standard dosing schedule, whereas 60
subjects received the standardized prednisone dosing sched-
ule alone. An effect favoring thymectomy was seen in both of
the coprimary outcome measures: reductions in the time-
weighted average quantitative MG (QMG) score and the
time-weighted average alternate-day prednisone dose. Sec-
ondary outcome measures, including azathioprine use, in-
travenous immunoglobulin (IVIg) use, and hospitalizations
for MG exacerbations, also favored thymectomy plus pred-
nisone. Benefits were seen within the first year and were
sustained through year 3. In a post hoc analysis, neither the
Table 1 Drugs to Avoid or Use With Caution in MGa
Drug Comment
Aminoglycoside antibiotics (e.g., gentamycin, neomycin, and
tobramycin)
Used for gram-negative bacterial infections. May worsenMG. Use cautiously
if no alternative treatment available.
Beta-blockers Commonly prescribed for hypertension, heart disease, and migraine but
potentially dangerous in MG. May worsen MG. Use cautiously.
Botulinum toxin Presynaptic neuromuscular junction blocker. Avoid use.
Chloroquine and hydroxychloroquine Used to treat/prevent malaria and for certain autoimmune diseases. May
precipitate de novoMG or worsen preexisting MG. Use only if necessary and
observe for worsening.
Corticosteroids A standard treatment for MG but may cause transient worsening within the
first 2 weeks. Monitor carefully for this possibility.
Desferrioxamine (deferoxamine) Chelating agent used for hemochromatosis. May worsen MG.
D-Penicillamine Used for Wilson disease and rarely for rheumatoid arthritis. Strongly
associated with causing MG. Avoid use.
Fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin,
moxifloxacin, and ofloxacin)
Commonly prescribed broad-spectrum antibiotics that are associated with
worsening MG. The US FDA has designated a “black-box” warning for these
agents in MG. Use cautiously, if at all.
Immune checkpoint inhibitors (e.g., ipilimumab, pembrolizumab,
atezolizumab, and nivolumab)
Used for certain cancers. Can precipitate de novo MG or worsen preexisting
MG. Use with caution as determined by oncologic status.
Iodinated radiologic contrast agents Older reports document increased MG weakness, but modern contrast
agents appear safer. Use cautiously and observe for worsening.
Macrolide antibiotics (e.g., erythromycin, azithromycin, and
clarithromycin)
Commonly prescribed antibiotics for gram-positive bacterial infections. May
worsen MG. Use cautiously, if at all.
Magnesium Potentially dangerous if given intravenously, i.e., for eclampsia during late
pregnancy or for hypomagnesemia. Use only if absolutely necessary and
observe for worsening.
Procainamide Used for irregular heart rhythm. May worsen MG. Use with caution.
Quinine Occasionally used for leg cramps. Use prohibited except in malaria in the
United States.
Statins(e.g., atorvastatin, pravastatin, rosuvastatin, and simvastatin) Used to reduce serum cholesterol. May rarely worsen or precipitate MG.
Evaluate closely for worsening MG when statin treatment is commenced.
Telethromycin Antibiotic for community-acquired pneumonia. Associated with hepatoxicity
and risk of prolonged QTc interval. Causes severe, often fatal worsening in
MG. Had been given a “black-box” warning by the US FDA contraindicating
use in MG. Drug withdrawn from most markets internationally. Should not
be used in MG.
Live-attenuated vaccines (measles, mumps, rubella, varicella zoster,
intranasal influenza, oral polio, adenovirus type 4 and 7, Zostavax
(herpes zoster), rotavirus, oral typhoid, smallpox, and yellow fever)
Do not affect MG but are contraindicated in patients on immunosuppressive
treatments because of the risk for adverse reactions due to uninhibited
growth of the attenuated live virus or bacteria.
Abbreviation: MG = myasthenia gravis.
a Many drugs are associatedwithworsening ofMG.However, reported associations do not necessarilymean thesemedications should never be prescribed in
MG. Reports are often rare or represent a coincidental association. Clinical judgment and the risk-to-benefit ratio of the drug should be considered when it is
deemed important for a patient’s treatment. Listed above are medications that have the strongest evidence for worsening MG.
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prednisone dose nor QMG scores were significantly different
between the 2 treatment groups in patients 50 years or older.3
An extension of the MGTX trial followed 68 (61%) partici-
pants from the original trial for 2 additional years. At 60
months, lower time-weighted average QMG scores and a
reduction in average time-weighted prednisone dose favored
thymectomy plus prednisone.4 A recent AAN Practice Advi-
sory recommended that clinicians should discuss thymectomy
with patients with AChR-Ab+ generalized MG and should
counsel patients considering minimally invasive thymectomy
techniques that it is uncertain whether the benefit attained by
extended transsternal thymectomy will also be attained by
minimally invasive approaches (level B).5
Recommendations
1. a. In nonthymomatous, generalized MG patients with
AChR-Ab, aged 18–50 years, thymectomy should be
considered early in the disease to improve clinical
outcomes and tominimize immunotherapy requirements
and the need for hospitalizations for disease exacerba-
tions (median 9, range 2–9). b. Thymectomy should be
strongly considered in patients with AChR-Ab+ gener-
alized MG if they fail to respond to an initial adequate
trial of immunotherapy or have intolerable side effects
from that therapy (median 9, range 5–9).
2. Thymectomy for MG is an elective procedure and should
be performed when the patient is stable and deemed safe
to undergo a procedure where postoperative pain and
mechanical factors can limit respiratory function (median
9, range 8-9).
Recommendations 4 and 5 below are unchanged from the
2016 consensus guidance.1
3. Endoscopic and robotic approaches to thymectomy are
increasingly performed and have a good track record for
safety in experienced centers. Data from randomized,
controlled comparison studies are not available. Based on
comparisons across studies, less invasive thymectomy
approaches appear to yield similar results to more
aggressive approaches (median 9, range 4–9).
4. Thymectomy may be considered in patients with general-
izedMGwithout detectable AChR-Ab if they fail to respond
adequately to immunosuppressive (IS) therapy or to avoid/
minimize intolerable adverse effects from IS therapy.
Current evidence does not support an indication for
thymectomy in patients withMuSK, low-density lipoprotein
receptor–related protein 4, or agrin antibodies (median 9,
range 6–9) (table e-3, doi:10.5061/dryad.6hdr7sqxx).
Ocular MG
A small RCT comparing prednisone with placebo in patients
with 11 ocular MG who had previously failed to achieve
minimal manifestation (MM) status after 4–6 weeks of pyr-
idostigmine found that 5 of 6 participants (83%) in the
prednisone group achieved the primary end point of sustained
MM status at a median of 14 weeks on prednisone (median
dose 15 mg/d), compared with none of 5 in the placebo
group.6 Three of the 5 placebo participants switched to
prednisone (60 mg/d) with rapid taper; 2 attained sustained
MM status. A prospective cohort study of 13 consecutive
ocular and 76 generalized MG patients evaluated the effect of
IS agents on ophthalmoparesis.7 Fifty-nine percent of patients
had complete resolution of ophthalmoparesis within 12 ± 2
months of initiation of IS agents. Patients with milder oph-
thalmoparesis had greater odds of symptom resolution in the
first year of treatment. Median time to resolution was 7
months after IS agents were started.
Evidence for the efficacy of thymectomy in ocular MG is
limited by the retrospective design of most published studies.
In a case-control study of 47 patients with nonthymomatous
ocular MG who underwent thymectomy matched to 67 pa-
tients who refused surgery, there was no difference in the
proportion of patients achieving stable remission at a median
follow-up of 100–116 months.8 A retrospective analysis of
236 patients with thymomatous and nonthymomatous MG
reported no improvement after thymectomy in 25 patients, of
whom 17 (68%) were ocular or predominantly ocular, over 12
months of follow-up.9 In another retrospective case series of
52 patients with MG, only 2 of 11 patients with ocular MG
(18%) achieved remission after thymectomy, in contrast to
28%–50% of patients with generalized MG.10
A retrospective case series of 110 patients with ocular MG
who underwent extended transsternal thymectomy reported
that at a median follow-up of 33.5 months, 26% achieved
complete remission (defined as asymptomatic without
medications for 12 months).11 Five patients had a thy-
moma.11 A retrospective case series of 49 nonthymomatous
ocular MG and 12 ocular MG with thymoma undergoing
thymectomy followed for a mean duration of 9 years
reported a cure defined as asymptomatic without the need
for medications in 51%.12 In yet another retrospective case
series of transcervical thymectomy in MG, 57% of 12 pa-
tients with ocular MG achieved MGFA postintervention
status (PIS) of complete stable remission (CSR)13 at 5
years.14 A subsequent case series of 151 patients with MG
who underwent transcervical thymectomy followed for 5
years showed a higher odds ratio for remission in ocular MG
compared with generalized MG without controlling for
other variables (analysis performed by P.N.).15 In 12 pa-
tients with ocular MG undergoing thymectomy because of
an abnormal chest CT scan, all but one required additional
immunosuppression after thymectomy; 6 achieved re-
mission at a mean follow-up of 81 months.16 In a retro-
spective analysis of 50 patients with juvenile MG undergoing
thymectomy, of whom 46% were ocular, 50% showed im-
proved PIS at a mean of 3.5 years of follow-up.17 There was
no difference between ocular and generalizedMG. In a meta-
analysis of 26 studies of thymectomy in nonthymomatous
MG, the pooled CSR rate was 0.51.18 There was high het-
erogeneity in the meta-analysis model, indicating substantial
differences among the included studies.
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Recommendations
1. Ophthalmoparesis or ptosis in ocular MG that is not
responding to anticholinesterase agents should be treated
with immunosuppressant agents if symptoms are
functionally limiting or troublesome to the patient
(median 9, range 7–9).
2. Corticosteroids should be used as the initial IS agent in
ocular MG. Steroid-sparing IS agents may be needed
when corticosteroids alone are ineffective, contraindi-
cated, or not tolerated (median 9, range 6–9).
3. Data from a single small RCT suggest that low-dose
corticosteroids may be effective for ocular MG and may
avoid side effects associated with high-dose corticoste-
roids (median 9, range 4–9).
4. AChR-Ab+ patients with ocular MG who do not respond
adequately to acetylcholinesterases and who either prefer
not to take IS therapy or have contraindications to or are
refractory to IS agents may be offered thymectomy (median
8, range 5–9) (table e-10, doi:10.5061/dryad.6hdr7sqxx).
Rituximab
Most studies of RTX are retrospective, and some combine pa-
tients with AChR-Ab, MuSK-Ab, and seronegative MG. A
multicenter blinded prospective review of MuSK-Ab + MG
patients demonstrated that 14 of 24 (58%) patients treated with
RTX achieved MM status and required only low-dose IS ther-
apy, compared with 5 of 31 (16%) of the non-RTX group.19
In a prospective open-label study of 22 refractory AChR-Ab+,
MuSK-Ab+, and seronegative MG, MG manual muscle testing
(MMT) scores revealed significant improvement frombaseline at
a mean follow-up of 29 ± 19 months in the AChR-Ab+ and
MuSK-Ab+ groups.20 Another prospective open-label study of 14
patients with refractory AChR-Ab+, MuSK-Ab+, and seronega-
tiveMG reported improvement inMMTscores at amean follow-
up of 22 months.21 The time to peak response after a single cycle
of RTX was 4.5 ± 1 months. A retrospective multicenter study of
MuSK-Ab+MGreported that RTXgiven in the dose of 375mg/
m2 weekly for 4 weeks and then monthly for the next 2 months
was associated with lower relapse rates (18%) compared with a
regimen of two 1 g infusions separated by 2 weeks (80%).22 A
retrospective Austrian nationwide study of 56 patients with
AChR-Ab+ and MuSK-Ab + MG reported that 26% of patients
were in remission 3 months after treatment with varying dosing
protocols of RTX. At a median of 20 months, 43% were in
remission and 25% achieved MM status.23 A single-center ret-
rospective study of 21 AChR-Ab+, 3 MuSK-Ab+, and 4 patients
with double-seronegative MG found that muscle strength im-
proved significantly from baseline at 6months and then stabilized
up to 36 months, and PIS was improved in 43% at 6 months.24 A
retrospective combined analysis of previously published case re-
ports of 169 patients between January 2000 and August 2015
reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+
MG patients treated with RTX achieved MM status or better.25
The number of cycles of RTX varied but did not have an effect on
the response. A recent systematic review of previous studies of
165 patients with AChR-Ab+ MG treated with RTX concluded
that despite heterogeneous outcomemeasures, significant clinical
improvement was seen in 113 patients (68%), with 36%
achieving remission.26 A phase II RCT of RTX (Beat-MG) en-
rolled 52 patients with generalized nonthymomatous AChR-Ab+
MGon a stable regimen of prednisone for 4 weeks or prednisone
plus another IS agent for 6 months.27 Two cycles of RTX 6
months apart were compared to placebo with the primary out-
come being a steroid-sparing effect (≥75% reduction in mean
daily prednisone requirements in the 4 weeks before week 52
compared with the 4-week period before randomization). The
studywas designed to assess futility (nonsuperiority). Preliminary
results reported that the area under the curve for prednisone was
not significantly different between RTX and placebo groups, with
60% on RTX and 56% on placebo achieving the primary out-
come. There were no significant differences in mean QMG or
MG-composite (MGC) changes between the groups. The study
suggests that in mildly to moderately symptomatic generalized
AChR-Ab+ MG, RTX is unlikely to have a clinically meaningful
steroid-sparing effect over 12 months.
Three cases of progressive multifocal leukoencephalopathy
have been reported in MG. One was RTX related, although
the patient had previously received other IS agents,28 another
patient was on azathioprine and prednisone,29 and the third
patient was on prednisolone, IVIg, and azathioprine.30
Recommendations
Recommendation 1 is unchanged from the 2016 consensus
guidance.1
1. Rituximab should be considered as an early therapeutic
option in patients with MuSK-Ab+ MG who have an
unsatisfactory response to initial immunotherapy (me-
dian 9, range 4–9).
2. The efficacy of RTX in refractory AChR-Ab+ MG is
uncertain. It is an option if patients fail or do not tolerate
other IS agents (median 8, range 4–9) (tables e-2 and e-7,
doi:10.5061/dryad.6hdr7sqxx).
Methotrexate
Studies on the use of MTX in MG are limited, and the available
data do not provide convincing evidence of efficacy. In a ret-
rospective case series of 16 patients withMG treated withMTX,
(abstract only) 8 patients reduced pyridostigmine doses and 6
showed “clinical improvement.”31 A prospective open-label case
series published only as an abstract reported that 14 of 16
patients with MG treated with MTX had an improved PIS on a
mean follow-up of 20.6 months.32 In a single-blinded trial, 24
patients with generalized MG on prednisone were randomized
toMTX (11) or azathioprine (13).33 At 24 months, the average
prednisone dose required to achieve and maintain MM status
was lower in both MTX- and azathioprine-treated patients but
was not different between the groups. At months 10 and 12, the
prednisone dose was lower in the MTX group, but the confi-
dence interval includes clinicallymeaningful and nonmeaningful
effects. Similar proportions of both groups achievedMM status,
and there were no differences in QMG or MG-activity of daily
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living (MG-ADL) scores between the groups.33 An RCT en-
rolled 50 patients with AChR-Ab+ MG taking prednisone at a
dose of ≥10 mg/d.34 Patients were randomized 1:1 to MTX 20
mg/wk or placebo. There was no difference in the primary
outcome measure, the area under the prednisone dose-time
curve between months 4 and 12, and the mean 12-month
change in QMG, MMT, MG-Quality of life, MG-ADL, and
MGC was no different between treatment groups.
Recommendation
1. Although evidence from RCTs is lacking, oral MTX may
be considered as a steroid-sparing agent in patients with
generalized MG who have not tolerated or responded to
steroid-sparing agents that are better supported by RCT
data (median 9, range 5–9) (table e-2, doi:10.5061/
dryad.6hdr7sqxx).
Eculizumab
Eculizumab is a humanized monoclonal antibody against the
terminal C5 complement molecule.35 Eculizumab prevents the
formation of the membrane attack complex and reduces damage
caused by complement-fixing AChR antibodies.36 In a phase II
crossover RCT of 14 patients with refractory generalized AChR-
Ab + MG, at the end of the first treatment period, 6/7 (86%) of
eculizumab-treated patients achieved the primary end point of a
2-point reduction in the QMG score, compared to 57% with
placebo.37 A repeatedmeasuresmixedmodel of data from all visits
revealed significant differences in the QMG score favoring eculi-
zumab. Eculizumab was well tolerated. In a phase III international
multicenter RCT of 125 patients with refractory generalized
nonthymomatous AChR-Ab+ MG (REGAIN), the primary
outcome measure of change in the MG-ADL score from baseline
to week 26, measured by worst-rank analysis of covariance, was
not significantly different (p = 0.0698) between eculizumab and
placebo arms.38 However, QMG score change on worst-rank
analysis of covariance, all prespecified secondary endpoints
(changes inQMG,MGC, andMG-QOL15 scores and responder
analyses of QMG and MG-ADL scores), and multiple sensitivity
analyses showed a significant benefit for eculizumab. Participants
who completed the 26-week REGAIN study were followed in an
open-label extension (OLE) within 2 weeks of completing
REGAIN.39 A preplanned interim analysis of the OLE at 22.7
months of median follow-up found a reduction in MG exacer-
bations by 75% compared with the year before REGAIN. In
addition, 56% (65/116) of patients achieved MM status or
pharmacologic remission. The magnitude of response on all
clinicalmeasures for the placebo patients in REGAINwho crossed
over to receive eculizumab in the OLE was similar to the
eculizumab-treated patients in REGAIN. A clinically meaningful
response in MG-ADL and QMG scores was seen in 55% and
39.7% of patients, respectively. Eculizumab was well tolerated.
One case of meningococcal meningitis occurred, despite vacci-
nation in the OLE and the patient was successfully treated.
Vaccination against Neisseria meningitidis (both meningococcal
conjugate Men ACWY and serogroup B or MenB) is required
at least 2 weeks before starting treatment with eculizumab. The
conjugate ACWY vaccines available in the United States in-
clude Menveo (1 dose, GlaxoSmithKline Biologicals, Inc.) and
Menactra (1 dose, single booster 4 years after initial dose if
needed, Sanofi Pasteur, Inc.). The 2 brands of MenB vaccine
are Bexsero (2 dose series, GlaxoSmithKline Biologicals, Inc.)
and Trumenba (3 dose series, Pfizer, Inc.). The brands are not
interchangeable, and a course should be completed with the
same brand of the vaccine for all doses. The vaccine does not
confer absolute protection against meningococcal meningitis.
Antibiotic coverage, for at least 4 weeks after immunization, is
recommended if eculizumab is started before the 2-week period
after vaccination. The recommendations for antibiotic coverage
vary. Penicillin VK 250–500 mg every 12 hours is usually the
first-line chemoprophylaxis.40,41 Erythromycin 500 mg twice
daily, azithromycin 500 mg daily, or ciprofloxacin 500 mg daily
are alternatives for penicillin-allergic patients.40–42 However,
both fluoroquinolones and macrolides can worsen MG. Che-
moprophylaxis of meningococcal infections in penicillin-
allergic patients can therefore be challenging, and infectious
disease consultation may be required.
Recommendations
1. Eculizumab should be considered in the treatment of
severe, refractory, AChR-Ab+ generalized MG (median
9, range 2–9).
2. The role of eculizumab in the treatment ofMG is likely to
evolve over time. Until further data become available to
allow comparisons of cost and efficacy with other
treatments, eculizumab should be considered after trials
of other immunotherapies have been unsuccessful in
meeting treatment goals (median 9, range 5–9).
3. Recommendations of the Advisory Committee on
Immunization Practices or other local guidelines re-
garding immunization against meningococcal meningitis
should be followed before treatment with eculizumab
(median 9, range 8–9).
4. Future research should include assessment of the duration
of eculizumab therapy necessary to achieve and maintain
treatment goals, its efficacy in otherMG populations (MG
with thymoma and seronegative MG), and in other stages
of disease (MG crises, exacerbations, and early therapy in
nonrefractory AChR-Ab+ MG) (median 8, range 4–9)
(table e-2, doi:10.5061/dryad.6hdr7sqxx).
Immune Checkpoint Inhibitors
Immune checkpoints (ICPs) aremost often inhibitory molecules
expressed on the surface of T cells, which modulate the immune
response and prevent host tissue damage due to uncontrolled
responses to foreign or self-antigens. The immune inhibitory
cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), pro-
grammed cell death protein 1 (PD-1), and programmed cell
death ligand 1 (PD-L1) are the best-characterized ICPs and are
targeted in cancer immunotherapy. CTLA-4 reduces T-cell ac-
tivation, competing with CD28 in binding B7 molecules (CD80
and CD86) on antigen-presenting cells. PD-1 binds its ligands
(PD-L1 and PD-L2) and reduces activated T-cell proliferation
through the inhibition of specific phosphorylation pathways.43,44
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Monoclonal antibodies against CTLA-4, PD-1, and PD-L1 act by
blocking these inhibitory ICP molecules to stimulate antitumor
immunity (immune checkpoint inhibitors [ICIs]). These include
the CTLA-4 inhibitor ipilimumab, PD-1 inhibitors pem-
brolizumab, nivolumab, and cemiplimab, and the PDL-1 inhibi-
tors atezolizumab, durvalumab, and avelumab. Because of the
upregulation of the immune response, multisystem immune-
related adverse events (irAEs) such as skin rash, thyroid dys-
function, pneumonitis, colitis, hepatitis, nephritis, hypophysitis,
and neurologic disorders including MG have been reported in
patients receiving checkpoint inhibitors.
The literature on irAEs of these drugs is rapidly evolving. De
novo MG has been reported in patients treated with anti–
CTLA-4 agents (ipilimumab),45 PD-1 inhibitors (nivolumab
or pembrolizumab),45–47 and with combined (anti–CTLA-4
plus anti–PD-1 or PD-L1) therapy.45 The estimated fre-
quency of MG among patients treated with PD-1 inhibitors
ranges from 0.12% to 0.2%.48–52 Exacerbation of preexisting
MG and subclinical AChR-Ab+ MG has been reported in
patients treated with PD-1 inhibitors.45,53,54
MG onset or exacerbation varies in severity and generally occurs in
the early phase of treatment. MG can overlap with other immune-
mediated peripheral and central neurologic syndromes.48,55 In a
review of the literature combinedwith a single-center experience, of
63 patients with MG due to ICIs, 52 had new-onset MG and 11
had a flare of preexisting MG. Most received PD-1 therapy. Con-
current myositis was diagnosed in 24 patients (37%) and myo-
carditis in 5 (8%); 2 had the triad of MG/myositis/myocarditis.
Median time from ICI initiation to developingMGwas 4 weeks (6
days–16 weeks). Respiratory failure requiring mechanical ventila-
tion occurred in 29 patients (45%). Patients with MG/myositis/
myocarditis developed respiratory failure more frequently than
those withMG alone (54% vs 42%). AChR-Ab titers were elevated
in 37/56 (66%) of tested patients. Three patients had AChR-Ab
when tested before ICI initiation and antibody titers increased at
least 2-fold after ICI initiation. Intravenous corticosteroids were
used in 59 of 63 patients. Thirty-eight patients received steroids as
first-line therapy and 24 (63%) improved. Four patients with ocular
MG developed respiratory insufficiency after corticosteroid treat-
ment. MG symptoms completely resolved in 12 patients (19%),
improved in 34 (55%), and worsened in 16 (26%).51 In a review of
1834 patients receiving ICIs, 4 had MG, of whom 1 was AChR-
Ab+. Three were associated withmyositis. Three patients withMG
received combined CTLA-4 and PD-1 ICIs and one received a
CTLA-4 ICI. Concurrent occurrence of MG with myocarditis and
thyroiditis was also noted.50 The diagnosis of ICI-related MG can
be challenging. Many patients with cancer have fatigue or gener-
alized weakness. The recognition of the underlying neuromuscular
disease may be delayed by the focus on the oncologic illness.
Concurrent myositis maymakeMG difficult to diagnose especially
when associated with ocular and bulbar weakness. Seronegative
MG appears to be more frequent in these patients, making the
diagnosis even more challenging.50 The severity of the illness may
be the result of multiple concurrent conditions including MG,
myositis, and myocarditis. CNS involvement may occur in
conjunction with MG or MG-myositis overlap.50 Corticosteroid
therapy appears to result in favorable outcomes.50
Recommendations
1. The risk of MG and other immune-mediated neurologic
illnesses should be discussed with patients who are
candidates for ICIs (median 9, range 5–9).
2. At this time, there is no evidence to either support or
refute the utility of AChR antibody testing in patients
without MG before starting ICIs (median 8, range 7–9).
3. MG associated with ICIs is generally severe, with a high
rate of respiratory crises (median 8, range 5–9).
4. Preexisting MG does not constitute an absolute
contraindication to the use of ICIs, at least in patients
with well-controlled disease (MM status or better).
However, in these patients:
 It may be prudent to avoid combined therapy
(anti–CTLA-4 plus anti-PD-1/PD-L1 monoclonal
antibodies), given the higher potential for severe irAEs.
 Close clinical monitoring, particularly of respiratory
and bulbar function, is mandatory.
 Although the therapeutic response to ICIs seems to be
less satisfactory in patients receiving immunosuppres-
sants, MG treatment should be maintained and may
even be restarted in patients whoseMG is in remission
before treatment with ICIs (median 8, range 5–9).
5. Early aggressive treatment with high-dose steroids in
combination with plasma exchange or IVIgmay be required
in patients who develop overt MG while on ICIs. The
decision to withdraw ICIs is determined by the oncologic
status (median 8, range 7–9) (table e-9, doi:10.5061/dryad.
6hdr7sqxx).
Discussion
This is an updated formal international consensus guidance of
MG experts, based on new evidence that has become available
since the initial guidance was published in 2016.1 As before,
these statements are intended as a guide for clinicians
worldwide and are not absolute recommendations for man-
agement. They are also not intended for establishing payment
policies or drug tiering by payers. This continues to be a living
document, which will require periodic review and updates to
reflect new information relevant to the management of MG.
Acknowledgment
The authors acknowledge the support of the Myasthenia
Gravis Foundation of America.
Study Funding
No targeted funding reported.
Disclosure
P. Narayanaswami: Research support: Momenta Pharmaceu-
ticals, PCORI, Advisory board: Argenx, Alexion, Member,
120 Neurology | Volume 96, Number 3 | January 19, 2021 Neurology.org/N
Medical and Scientific Advisory Board, and Myasthenia Gravis
Foundation of America (MGFA). D.B. Sanders: Research
support from PCORI, Consultant for Accordant Health Ser-
vices, Alexion, Cabaletta, Janssen RnD, Kashiv Biosciences, and
Momenta Pharmaceuticals. G.I. Wolfe: Advisory board for
Grifols, Alexion, Takeda, BPL, UCB, ArgenX, Ra. Research
support from ArgenX, Ra, Immunovant, and MGFA. M.
Benatar: Advisory Boards: Immunovant, Viela Bio; Site-PI on
industry trials: UCB; federal funding: Site-PI for MGNet
(U54115054). G. Cea: No relevant disclosures. A. Evoli: Sci-
entific award jury member for Grifols and a safety data monitor
for UCB. N. E.Gilhus: Consultant for Ra Pharma, Argenx, and
UCB. Speakers’ honoraria from Octapharma, Alexion, and
Merck Serono. I. Illa: Consultant and Scientific award jury
member for Grifols; N. L. KuntzL: Medical advisory boards for
Argenx, Audentes, AveXis, Biogen, Cytokinetics, Roche, and
Sarepta; J.M.Massey: Site PI, Revance Therapeutics.Melms A:
Advisory board, UCB; H. Murai: Consultant for Alexion,
Argenx, and Ra, speaker honoraria from the Japan Blood
Products Organization, research support from the Ministry of
Health, Labour and Welfare, Japan. J. Palace: partly funded by
highly specialized services to run a national congenital myas-
thenia service and a neuromyelitis service, support for scientific
meetings and honorariums for advisory work from Merck
Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, and
Bayer Schering, Alexion, Roche, Genzyme, MedImmune,
EuroImmun, MedDay, Abide ARGENX, UCB and Viela Bio
and grants from Merck Serono, Novartis, Biogen Idec, Teva,
Abide, MedImmune, Bayer Schering, Genzyme, Chugai, and
Alexion. She has received grants from the MS society, Guthrie
Jackson Foundation, NIHR, Oxford Health Services Research
Committee, EDEN, MRC, GMSI, John Fell, and Myaware for
research studies. D. P. Richman: Research funding from the
NINDS (1R21NS104516), Myasthenia Gravis Foundation of
America, and Cabaletta Bio Inc.Member of the Advisory Board
of Cabaletta Bio Inc. J. Verschuuren: receives financial support
from Target to B consortium, Prinses Beatrix Spierfonds, and
has been involved in trials or consultancies for Argenx, Alexion,
or Ra pharma. Member of the European Reference Network
for Rare Neuromuscular Diseases [ERN EURO-NMD]. Go to
Neurology.org/N for full disclosures.
Publication History





























Gil Wolfe, MD Univ. at Buffalo Jacobs
School of Medicine and
Biomedical Sciences,
















Gabriel Cea, MD Facultad de Medicina,
Universidad de Chile,
Santiago, Chile

























NMD and CIBERER U762,
Spain

































of Health and Welfare,
Narita, Japan































Neurology.org/N Neurology | Volume 96, Number 3 | January 19, 2021 121
References
1. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for man-
agement of myasthenia gravis: executive summary. Neurology 2016;87:419–425.
2. Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method
User’s Manual. [online]. Available at: rand.org/pubs/monograph_reports/MR1269.
html. Accessed July 10, 2020.
3. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myas-
thenia gravis. N Engl J Med 2016;375:511–522.
4. Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus pred-
nisone versus prednisone alone in patients with non-thymomatous myasthenia gravis:
2-year extension of the MGTX randomised trial. Lancet Neurol 2019;18:259–268.
5. Gronseth GS, Barohn R, Narayanaswami P. Practice advisory: thymectomy for my-
asthenia gravis (practice parameter update): report of the guideline development,
dissemination, and implementation subcommittee of the American Academy of
Neurology. Neurology 2020;94:705–709.
6. Benatar M, McDermott MP, Sanders DB, et al. Efficacy of prednisone for the treat-
ment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle
Nerve 2016;53:363–369.
7. Europa TA, Nel M, Heckmann JM. Myasthenic ophthalmoparesis: time to resolution
after initiating immune therapies. Muscle Nerve 2018;58:542–549.
8. Mineo TC, Ambrogi V. Outcomes after thymectomy in class I myasthenia gravis.
J Thorac Cardiovasc Surg 2013;145:1319–1324.
9. Evoli A, Batocchi AP, Provenzano C, Ricci E, Tonali P. Thymectomy in the treatment
of myasthenia gravis: report of 247 patients. J Neurol 1988;235:272–276.
10. Hatton PD, Diehl JT, Daly BDT, et al. Transsternal radical thymectomy for myas-
thenia gravis: a 15-year review. Ann Thorac Surg 1989;47:838–840.
11. Liu Z, Feng H, Yeung S-CJ, et al. Extended transsternal thymectomy for the treatment
of ocular myasthenia gravis. Ann Thorac Surg 2011;92:1993–1999.
12. Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular
myasthenia gravis. J Thorac Cardiovasc Surg 2001;122:562–568.
13. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for
clinical research standards. Task Force of the medical scientific advisory board of the
Myasthenia Gravis Foundation of America. Neurology 2000;55:16–23.
14. Shrager JB, Deeb ME, Mick R, et al. Transcervical thymectomy for myasthenia gravis
achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg 2002;
74:320–326; discussion 326-327.
15. Shrager JB, Nathan D, Brinster CJ, et al. Outcomes after 151 extended transcervical
thymectomies for myasthenia gravis. Ann Thorac Surg 2006;82:1863–1869.
16. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term
immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997;62:156–162.
17. Kim AG, Upah SA, Brandsema JF, Yum SW, Blinman TA. Thoracoscopic thymec-
tomy for juvenile myasthenia gravis. Pediatr Surg Int 2019;35:603–610.
18. Zhu K, Li J, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-
thymomatous ocular myasthenia gravis: a systematic review andmeta-analysis. Neurol
Sci 2017;38:1753–1760.
19. Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-
MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 2017;
89:1069–1077.
20. Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis:
extended prospective study results. Muscle & Nerve 2018;58:452–455.
21. Anderson D, Phan C, Johnston WS, Siddiqi ZA. Rituximab in refractory myasthenia
gravis: a prospective, open-label study with long-term follow-up. Ann Clin Trans-
lational Neurol 2016;3:552–555.
22. Cortés-Vicente E, Rojas-Garcia R, Dı́az-Manera J, et al. The impact of rituximab
infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann
Clin Translational Neurol 2018;5:710–716.
23. Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia
gravis: a comprehensive nationwide study in Austria. J Neurol 2019;266:699–706.
24. Afanasiev V, Demeret S, Bolgert F, Eymard B, Laforet P, Benveniste O. Resistant
myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients.
Neuromuscul Disord 2017;27:251–258.
25. Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia
gravis: a systematic review. Muscle Nerve 2017;56:185–196.
26. Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab
in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psy-
chiatry 2020;91:392–395.
27. Nowak RJ, Coffey C, Goldstein J. AAN 2018 Emerging science abstracts: B‐cell
targeted treatment in myasthenia gravis (BeatMG)—a phase 2 trial of rituximab in
myasthenia gravis: topline results. Neurology 2018;90:e2182–e2194.
28. Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis
treated with multiple immunosuppressing agents. Neurol Clin Pract 2016;6:e17–e19.
29. Dawson DM. Progressive multifocal leukoencephalopathy in myasthenia gravis. Ann
Neurol 1982;11:218–219.
30. Gedizlioglu M, Coban P, Ce P, Sivasli IE. An unusual complication of immunosup-
pression in myasthenia gravis: progressive multifocal leukoencephalopathy. Neuro-
muscul Disord 2009;19:155–157.
31. Hartman J, Rivner MH. Methotrexate in myasthenia gravis. Clin Neurophysiol 2009;
120:e123–e124.
32. Abdou A. Methotrexate for treatment of myasthenia gravis. Neurology 2007;68:A300.
33. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of
methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia
gravis. BMC Neurol 2011;11:97.
34. Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for
patients with generalized myasthenia gravis. Neurology 2016;87:57–64.
35. Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs 2018;78:
367–376.
36. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of
the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal
hemoglobinuria. Nat Biotechnol 2007;25:1256–1264.
37. Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-
controlled phase II study of eculizumab in patients with refractory generalized my-
asthenia gravis. Muscle Nerve 2013;48:76–84.
38. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in
anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis
(REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre
study. Lancet Neurol 2017;16:976–986.
39. Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculi-
zumab in generalized myasthenia gravis. Muscle Nerve 2019;60:14–24.
40. Meningococcal infection and eculizumab/complement inhibitors [online]. Available
at: pnhleeds.co.uk/professionals/meningococcal-infection-and-eculizumab-comple-
ment-inhibitors/. Accessed July 10, 2020.
41. Benamu E, Montoya JG. Infections associated with the use of eculizumab: recom-
mendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319–329.
42. Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Mateczun A. Azithromycin
compared with rifampin for eradication of nasopharyngeal colonization by Neisseria
meningitidis. Pediatr Infect Dis J 1998;17:816–819.
43. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer
therapy. J Clin Oncol 2015;33:1974–1982.
44. Topalian SL. Targeting immune checkpoints in cancer therapy. JAMA 2017;318:
1647–1648.
45. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of
immune checkpoint inhibitors. Eur J Cancer 2017;82:128–136.
46. Mohn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological im-
mune related adverse events associated with nivolumab, ipilimumab, and pem-
brolizumab therapy-review of the literature and future outlook. J Clin Med 2019;8:
1777.
47. Moreira A, Loquai C, Pfohler C, et al. Myositis and neuromuscular side-effects in-
duced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12–23.
48. Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed
cell death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep 2018;18:63.
49. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with
myositis and myocarditis in Japan. Neurology 2017;89:1127–1134.
50. Dubey D, David WS, Reynolds KL, et al. Severe neurological toxicity of immune
checkpoint inhibitors: growing spectrum. Ann Neurol 2020;87:659–669.
51. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myas-
thenia gravis: single center experience and systematic review of the literature.
J Immunother Cancer 2019;7:319.
52. Xu M, Nie Y, Yang Y, Lu YT, Su Q. Risk of neurological toxicities following the use of
different immune checkpoint inhibitor regimens in solid tumors: a systematic review
and meta-analysis. Neurologist 2019;24:75–83.
53. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune
checkpoint Inhibitors in the treatment of patients with cancer and preexisting auto-
immune disease. Ann Intern Med 2018;169:133–134.
54. Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe exacerbation of myasthenia
gravis associated with checkpoint inhibitor immunotherapy. J Neuromuscul Dis 2017;
4:169–173.
55. Puwanant A, Isfort M, Lacomis D, Zivkovic SA. Clinical spectrum of neuromuscular













122 Neurology | Volume 96, Number 3 | January 19, 2021 Neurology.org/N
